| Budget Amount *help |
¥6,200,000 (Direct Cost: ¥6,200,000)
Fiscal Year 2002: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2000: ¥3,200,000 (Direct Cost: ¥3,200,000)
|
|---|
| Research Abstract |
(1) The changes in histology, proliferative activity, and apoptosis of thymoma due to steroid pretreatment were examined. In addition to lymphocyte depletion, the tumor cell morphology was also changed with increased apoptotic cells and decreased proliferative cells (Virchows Arch, 2001).
(2) Clinical usefulness of WHO classification of thymic epithelial tumors was ascertained. Immature T lymphocytes in each WHO subtype were quantified by flow cytometry to evaluate the functional aspect of tumors (Am J Surg Pathol, 2001).
(3) In a large series of patients with thymoma, each of Masaoka's staging and WHO classification was found to be an independent prognostic factor by multivariate analysis (Cancer, 2002).
(4) In micronodular thymic epithelial tumors with stromal lymphoid infiltration, a spectrum ranging from benign tumor to lymphoepithelioma-like carcinoma was found. Association with EB virus was not detected (Histopathology, 2001).
(5) Two rhabdomyosarcoma-like thymic tumors were proved to be carcinosarcoma by immunohistochemistry, electron microscopy, and karyotyping (Histopathology, 2002).
(6) MALT lymphoma of the thymus is rare and not well established. Fifteen cases were clinicopathologically and genetically analyzed (Am J Pathol, 2002).
(7) In collaborative work with radiologists, some correlation between WHO subtypes of thymic epithelial tumors and CT findings was detected (Am J Roentgenol, 2002)
|
